Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE)

Hepatocellular carcinoma (HCC) is the most widely recognized kind of essential liver growth in grown-ups and is the most well-known reason for death in individuals with cirrhosis. It happens in the setting of incessant liver aggravation and is most firmly connected to endless viral hepatitis contamination (hepatitis B or C) or introduction to poisons, for example, liquor or Aflatoxin. Certain ailments, for example, hemochromatosis and alpha 1-antitrypsin lack, particularly increment the danger of treating HCC. Similarly, as with any malignancy, the treatment and forecast of HCC differ contingent upon the specifics of tumor histology, measure, how far growth has spread, and in general wellbeing. 

  • HCC Management
  • Immune Therapy
  • Molecular Targeted Agents
  • Advanced Stages
  • Sorafenib

Related Conference of Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE)

January 30-31, 2019

16th World Congress on Gastroenterology & Therapeutics

Bangkok, Thailand
January 30-31, 2019 |

World Congress on Pancreatic Cancer and Liver Diseases

Radisson Hotel Narita | Tokyo, Japan
March 04-05, 2019

20th World Congress on Gastroenterology

Berlin, Germany
April 24-25, 2019

International conference on Liver and Hepatitis

Budapest, Hungary
May 15-16, 2019

21st World Congress on Advances in Gastroenterology and Hepatology

Mercure Melbourne Albert Park, Melbourne, Australia
July 08-09, 2019

14th Euro-Global Gastroenterology Conference

Zurich, Switzerland
July 15-16, 2019

7th International Conference on Hepatology

Sydney, Australia
September 23-24, 2019

World Summit on Liver Cirrhosis and Hepatitis

Tokyo, Japan
October 14-15, 2019

19th World Gastroenterologists Summit

Sydney, Australia

Hepatocellular Carcinoma (HCC) and Transarterial ChemoEmbolization (TACE) Conference Speakers

Recommended Sessions

Related Journals

Are you interested in